Mutational Signature‐Based Biomarker for Phase <scp>II</scp> Trial of Olaparib Maintenance in Advanced High‐Grade Ovarian CancerKatsutoshi Oda, Kosei Hasegawa, Akira Nishijima et al.|Cancer Science|2026Cited by 0